Voxelotor open-label extension in sickle cell disease

Phase 3, open-label, single-arm trial of voxelotor in sickle cell disease (SCD), sponsored by Pfizer. Primary endpoints: Number of Participants With Sickle Cell Disease-Related Treatment Emergent Adverse Events up to 300.7 weeks, Number of Participants With Non-Sickle Cell Disease-Related Treatment Emergent Adverse Events up to 300.7 weeks and 4 more. Started Jun 2018; status: terminated.